On January 30th, Takeda Pharmaceutical announced the appointment of Liu Yan as President of Takeda China, responsible for the overall strategy and business development of Takeda China. She also became a member of the management committee of the newly established Takeda Pharmaceutical International Business Division.
Liu Yan has over fifteen years of management experience in the pharmaceutical industry. She joined Takeda in 2021 and has served as head of Takeda China’s Gastrointestinal Business Unit, Hemophilia and Rare Diseases Business Unit, and has been acting President of Takeda China since July 2025. Under her leadership and promotion, Takeda China has continued to accelerate the introduction of global products, explore innovative business models, and unlock the potential of digital technology, while continuously deepening industry ecosystem collaboration and firmly fulfilling its commitments to the Chinese market and patients.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Takeda Pharmaceuticals: Appoints Liu Yan as President of Takeda China
On January 30th, Takeda Pharmaceutical announced the appointment of Liu Yan as President of Takeda China, responsible for the overall strategy and business development of Takeda China. She also became a member of the management committee of the newly established Takeda Pharmaceutical International Business Division.
Liu Yan has over fifteen years of management experience in the pharmaceutical industry. She joined Takeda in 2021 and has served as head of Takeda China’s Gastrointestinal Business Unit, Hemophilia and Rare Diseases Business Unit, and has been acting President of Takeda China since July 2025. Under her leadership and promotion, Takeda China has continued to accelerate the introduction of global products, explore innovative business models, and unlock the potential of digital technology, while continuously deepening industry ecosystem collaboration and firmly fulfilling its commitments to the Chinese market and patients.